Crinetics Capex Per Share from 2010 to 2024

CRNX Stock  USD 56.09  0.03  0.05%   
Crinetics Pharmaceuticals Capex Per Share yearly trend continues to be fairly stable with very little volatility. Capex Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Crinetics Pharmaceuticals Capex Per Share regression line of annual values had r-squared of  0.33 and arithmetic mean of  0.03. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.08072876
Current Value
0.0848
Quarterly Volatility
0.02901572
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Interest Income of 14.1 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 4.02. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.
For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Latest Crinetics Pharmaceuticals' Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of Crinetics Pharmaceuticals over the last few years. It is Crinetics Pharmaceuticals' Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Slightly volatile
   Capex Per Share   
       Timeline  

Crinetics Capex Per Share Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.02
Coefficient Of Variation98.88
Mean Deviation0.02
Median0.01
Standard Deviation0.03
Sample Variance0.0008
Range0.0811
R-Value0.58
Mean Square Error0.0006
R-Squared0.33
Significance0.02
Slope0
Total Sum of Squares0.01

Crinetics Capex Per Share History

2024 0.0848
2023 0.0807
2022 0.0319
2021 0.0113
2020 0.006109
2019 0.0204
2018 0.0872

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Capex Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex Per Share 0.08  0.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.